+44 (0)20 3910 4640 hello@symmetron.net

Celia Sabry-Grant, MSc

Celia is a Health Outcomes Analyst. Since joining Symmetron in February 2018, she has gained experience in screening, data extraction, quality assessment and report writing for systematic reviews. Celia has an MSc in Public Health Nutrition from the University of Westminster, from which she graduated in 2014. Since graduating Celia has worked as a Nutritionist in foodservice, spent time volunteering with Action on Sugar and carried out research on cancer epidemiology and alcohol consumption.

Publications

Sabry-Grant, C., Malottki, K. & Diamantopoulos, A. The Cancer Drugs Fund in Practice and Under the New Framework. PharmacoEconomics 2019;37: 953

Laura M. Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B. Warren. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLOS ONE 2019

Sabry-Grant C, Malottki K, Diamantopoulos A. A review of recommendations for inclusion and data collection within the CDF framework (poster), International Society for Pharmacoeconomics and Outcomes Research Europe 2018, 10 – 14 November 2018, Barcelona, Spain.

Sawyer L, Malottki K, Yasmeen N, Wright E, Sabry-Grant C, Sohrt A, Ziegler F, Warren R. Interleukin-17 and interleukin-23 targeted treatments for moderate to severe plaque psoriasis:  a systematic review and network meta-analysis of PASI response (poster). European Academy of Dermatology and Venerology 27th Congress, 12-16 September 2018, Paris, France.